EarningsQ2 2026 Earnings Report
DE:5XE Q2 2026 EPS Results
Actual EPS€0.20
Consensus EPS€0.25
Beat/MissMissed by -€0.05
One Year Ago EPS€0.24
DE:5XE Q2 2026 Revenue Results
Actual Revenue€390.18M
Expected Revenue€362.20M
Beat/MissBeat by +€27.98M
YoY Revenue Growth+59.36%
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeAfter Close
Conference CallThursday, August 6, 2026
DE:5XE Upcoming Earnings
Extendicare's next earnings date is estimated for November 5, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
Overall the call conveyed a positive operational and financial trajectory: very strong revenue and adjusted EBITDA growth driven by the CBI acquisition and outsized home health volume expansion, improved liquidity and an upgraded unsecured capital structure, and redevelopment progress. These positives are tempered by near-term margin pressure in home health from necessary back-office and technology investments, one-time financing and transaction costs (including DSU settlement) that reduced reported net earnings and AFFO in the quarter, and ongoing integration work with associated costs and timing uncertainty. Management expects medium-term margin expansion and achievable synergies, and pro forma leverage and liquidity position the company well for execution.Company Guidance
Strong Top-Line and EBITDA Growth
Consolidated Q2 revenue increased 59.4% year-over-year to $611.0 million. Adjusted EBITDA rose to $68.3 million, up $28.5 million or 71.7% versus prior year, driven by acquisitions and organic growth.
Home Health Volume Surge and CBI Contribution
Home health volumes grew ~133% year-over-year (management cited 132.6% as well), with home health revenue up ~$202 million year-over-year. CBI (acquired Apr 1) contributed Q2 revenue of $146 million and adjusted EBITDA of $18.5 million; CBI ADV was 33.6k (run-rate ~12 million hours annually), ~20% ahead of 2024 volumes.
Organic Home Health Growth Ex-CBI
Excluding CBI, ADV increased 31.7% year-over-year, reflecting strong underlying market growth and contribution from the Closing the Gap acquisition.
Improved AFFO and Per-Share Cash Flow (Adjusted)
Reported Q2 AFFO increased 47% to $36.5 million. Excluding the one-time DSU cash withholding tax impact, AFFO would be $42.9 million (up ~73%) and AFFO per basic share would be $0.48, a 52.9% increase year-over-year.
Acquisitions Performing Above Underwriting
Three recent acquisitions (CBI, 9 LTC homes from Revera, and Closing the Gap) are exceeding originally underwritten adjusted EBITDA, reflecting effective acquisition selection and integration execution.
Stronger Capital Structure and Liquidity
Completed $450 million unsecured notes issuance (5-year at 4.345%, DBRS BBB stable) and new $250 million unsecured revolving facility. Pro forma net debt to adjusted EBITDA is ~2.5x (better than prior 3.3x outlook). Company exited Q2 with $208 million liquidity ($93M cash + $115M revolver availability), lowered weighted average interest rate by 80 bps to 4.4%, and increased weighted average term to 5.1 years.
Long-Term Care Redevelopment Progress
Opened Extendicare Beauclair (320 beds) and completed sale of Sudbury project to JV for net cash proceeds of $18.1 million, producing a $7.7 million after-tax gain. Six projects under construction and on track to open four new homes in 2027 (832 beds); 17 additional projects in planning under Ontario program.
Managed Services / SGP Growth
SGP customer base grew 8.3% year-over-year; SGP NOI margin at 57.6% with an expectation of annualized margins in the 50%–55% range. Managed services NOI improved to $9.9 million.
Integration Outlook and Synergy Targets
Management reports CBI tracking ahead of initial expectations and expects cost synergies of approximately $7.4 million once fully integrated; integration planning underway with an estimated 18–24 month timeline.
DE:5XE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed